Latest News and Press Releases

WILMINGTON, Del., Dec. 28, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Synthorx, Inc. (NASDAQ GS: THOR) regarding possible breaches of fiduciary duties...

BURLINGTON, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the second quarter 2016 before the market opens on Wednesday,...

BURLINGTON, Mass., July 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...

Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced its financial results for the first quarter of...

BURLINGTON, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced it will report financial results for the first quarter 2016 before the market opens on Wednesday, May...

BURLINGTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (Nasdaq:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of...

BURLINGTON, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it has entered into definitive agreements with certain institutional and accredited investors to raise...

BURLINGTON, Mass., Feb. 15, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced it will report financial results for the fourth quarter and full year 2015 before the market opens on...

BURLINGTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer and Dr. Brian Schwartz, Chief Medical Officer and Head of...

Orphan drug designation marks significant regulatory milestone for phase 2 trialAdditional response in phase 1b further validates development for ARQ 087 in cancers with FGFR2 genetic alterations ...